Valeritas Holdings Inc (NASDAQ:VLRX)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $0.48, but opened at $0.41. Valeritas shares last traded at $0.36, with a volume of 15,218 shares trading hands.
Several brokerages recently commented on VLRX. ValuEngine downgraded shares of Valeritas from a “buy” rating to a “hold” rating in a research note on Saturday, December 21st. Oppenheimer downgraded shares of Valeritas from an “outperform” rating to a “market perform” rating in a research note on Monday, December 23rd. Zacks Investment Research raised shares of Valeritas from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, BTIG Research cut shares of Valeritas from a “buy” rating to a “neutral” rating in a research report on Monday, December 23rd.
The company has a current ratio of 2.08, a quick ratio of 1.63 and a debt-to-equity ratio of 1.74. The company’s 50-day simple moving average is $0.63 and its 200-day simple moving average is $1.43. The stock has a market capitalization of $3.04 million, a price-to-earnings ratio of -0.03 and a beta of 1.72.
Valeritas (NASDAQ:VLRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.52) by $0.61. Valeritas had a negative net margin of 183.82% and a negative return on equity of 1,142.30%. The firm had revenue of $8.46 million during the quarter. On average, equities research analysts expect that Valeritas Holdings Inc will post -9.49 earnings per share for the current fiscal year.
In other Valeritas news, major shareholder Armistice Capital, Llc sold 1,060,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $0.75, for a total value of $795,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.02% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in VLRX. Wedbush Securities Inc. increased its position in shares of Valeritas by 449.1% during the fourth quarter. Wedbush Securities Inc. now owns 90,000 shares of the company’s stock worth $52,000 after buying an additional 73,609 shares during the period. Millennium Management LLC acquired a new stake in shares of Valeritas during the third quarter worth $77,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Valeritas during the second quarter worth $68,000. Hedge funds and other institutional investors own 18.18% of the company’s stock.
About Valeritas (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization.
Featured Story: S&P 500 Index
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.